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Background: Heparin-induced thrombocytopenia (HIT) is an adverse drug reaction associated with
thrombosis, and its paradoxical nature is a challenging issue for the diagnosis. The ‘4Ts’ scoring system
represents a simple and efﬁcient way to improve clinical diagnoses of the syndrome. This system classiﬁes
patients as having high, intermediate, and low clinical probability for HIT. However, uncertainty remains
concerning its clinical meaning, thus weakening the diagnostic value of this screening instrument.
Methods:We analyzed the diagnostic test accuracy based on individual patient data extracted from published
primary scientiﬁc studies. This study focused on 186 cases of treatment with heparin, which later evolved into
a clinical suspicion of HIT. Upon choosing the most appropriate reference laboratory, the accuracy of the 4Ts
was analyzed using the receiver operator characteristic curve analysis.
Results: Half of the positive cases (57.1%) were classiﬁed as having a high score, while 25.5% of the negative
cases were classiﬁed as a having low score for HIT. Slightly more than half of all patients (53.2%) were
classiﬁed as having an intermediate score. As such, the pre-test instrument would most likely fail to
distinguish between diseased and nondiseased patients in a relevant number of cases. The calculated accuracy
of the summary indicates that the 4Ts can be considered a good, but not a deﬁning, test.
Conclusion: Further studies are warranted regarding clinical score systems, either alone or in combination
with laboratory tests, in an attempt to improve the early diagnosis of this adverse drug reaction and to provide
better care for at-risk patients.
© 2011 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Heparin is the most commonly used anticoagulant in clinical
practices, in both treatment and prophylaxis approaches [1]. Heparin-
induced thrombocytopenia (HIT) is an immunologic reaction triggered
byheparin exposure and caused by antibodies (HIT antibodies)with the
ability to promote platelet activation and aggregation, in turn inducing a
state of hypercoagulability in the patient [2,3]. This represents a serious
adverse drug reaction deﬁned as an acquired prothrombotic disorder,
given that its occurrence results in a thrombocytopenia, which is
paradoxically associated with an increased risk for thromboembolic
complications.
The diagnosis of HIT is a challenging issue. It requires the
combination of clinical likelihood and laboratory tests to detect plateletudies (Cemed), Department of
ersity of Minas Gerais, Belo
ha, Av. Antônio Carlos, 6627,
inas Gerais, Brazil.
ira).
vier OA license.activation induced by HIT antibodies [4]. The 14C-serotonin released
assay (SRA), togetherwith theheparin-inducedplatelet activation assay
(HIPA), presents themost favourable sensitivity/speciﬁcity trade-off [5].
Thesemethods, known as functional assays, are able to demonstrate the
presence of clinically relevant HIT antibodies [6]. Another available
procedure is to detect HIT antibodies in the patient sera by means of
immunoassays. In the medical world today, a number of commercial
enzyme-linked immunoassays (ELISA) are available to diagnose HIT.
These immunoassays are able to detect pathogenic and non-pathogenic
antibodies and commonly lead to a high rate of false positives [6].
Despite their low speciﬁcity, these assays represent an ideal test to rule
out HIT.
The serotonin released assay is considered the gold standard for
diagnosing HIT [7]; however, it is time-consuming and technically
demanding. A more practical approach would be to perform an ELISA
test followed by a functional assay to conﬁrm a positive result. The
combination of an immunoassay with a functional assay improves
both sensitivity and speciﬁcity [8-10].
Regardless of the intrinsic strengths and weaknesses of the assays
available to diagnose HIT, the functional assays, as well as the
combination of an immunological assay with a functional assay, are
procedures generally considered to be reference standards to
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laboratory assays for HIT diagnosis are not available in many
institutions [11,12]. To improve the clinical diagnosis of HIT, a clinical
scoring system has been developed (Fig. 1) [13]. Using four clinical
features of HIT (magnitude of Thrombocytopenia, Timing of thrombo-
cytopenia regarding heparin exposure, occurrence of Thrombosis or
other sequelae, and the absence of other explanations for the
thrombocytopenia), the ‘4Ts’ scoring system represents a risk assess-
ment tool that classiﬁes patients within low, moderate, and high
probabilities for HIT. A prior study suggested that a low score is suitable
for ruling out HIT in most cases [14]. By contrast, a high score was not
always predictive of HIT, while an intermediate score required a more
accurate clinical judgment.
2. Methods
2.1. Patients and study design
An analysiswas performed based on individual patient data extracted
from published scientiﬁc studies carried out on patients treated with
heparin, which later evolved into a clinical suspicion of HIT. Studieswere
identiﬁed through electronic searches on Medline/PubMed, Web of
Science and Scopus, using the MESH terms ‘heparin’, ‘low-molecular-
weight heparin’ and ‘thrombocytopenia’, and the free terms ‘heparin’,
‘heparin-induced thrombocytopenia’, ‘case reports’, and ‘cases’ in
different combinations. Reference lists of papers and databases of thesis
and dissertations were also searched. Articles retrieved from these
searcheswere analysed to identify relevant individual patient datawhich
addressed HIT within case reports, clinical trials, and cohort studies. This
literature searchwas conducted in November 2008 andwas restricted to
English, Spanish, French, and Portuguese languages, as well as to articles
published after 1995.
2.2. Patient's characteristics and database construction
A database representing a nonconcurrent cohort [15] was
constructed based on individual patient clinical data extracted from
the relevant retrieved articles. The studies included herein followed a
process of rigorous platelet count monitoring and considered the
suspicion of HIT based on clinical events which most commonly
characterize HIT. Functional assays (SRA or the combination of an
ELISA and a functional assay) were applied as the reference diagnoses
for all positive cases. Negative cases conﬁrmed through ELISA testsFig. 1. Clinical score system (4Ts) developed for clinical assessment of heparin-induced throm
score between 0 and 8. Scores of 0 to 3, 4 to 5, and 6 to 8 are respectively classiﬁed as lowwere also accepted for inclusion. Cut-off points in the assays, as well as
the interpretation of the results, were based on the speciﬁc author's
criteria for each article. In addition, to be considered relevant to this
analysis, studies had to present sufﬁcient detailed individual clinical
data necessary for the application of the 4Ts scoring system.
Data were extracted according to a standard protocol, including
information on the age and sex of the patient, the type of heparin used
in the treatment (unfractionated heparin or low molecular weight
heparin), the baseline platelet count at the beginning of heparin
therapy, the platelet countwhenHITwas suspected, the daywhenHIT
was suspected, the history of previous exposure to heparin within the
last 100 days, clinical events related to HIT (thrombosis or other
complications diagnosed by clinical symptoms and objective methods
[16,17]), other causes that could explain the thrombocytopenia, and
results from laboratory assays. The relative reduction in the platelet
count was calculated using the baseline values and those found at the
moment HIT was suspected. In surgeries, the highest postoperative
platelet count before thrombocytopenia was considered whenever
possible. In cases when the description of clinical events did not
clearly consider the absence of other causes that could explain the
onset of thrombocytopenia, this situation was considered possible,
given that several drugs and clinical conditions can cause thrombo-
cytopenia in hospitalised patients receiving anticoagulant therapy.2.3. Statistical analysis
The 4Ts scoring system was applied to cases by an examiner who
was blinded to the deﬁnitive diagnosis. The resulting score was
computed to assure the correct classiﬁcation of the cases. The ability
of the 4Ts clinical scoring system to distinguish positive from
negative HIT cases was studied in terms of diagnostic accuracy using
a receiver operating characteristic curve (ROC curve). The ROC curve
investigates the accuracy of a model's ability to predict the presence
or absence of disease independent of the prevalence of positive
cases in the study population [18,19]. The 4Ts screening tool is a
continuous classiﬁer test that does not produce discrete positive or
negative results. Instead, it produces a numeric value on a continuous
scale varying from 0 to 8. To convert a continuous output value to a
binary label (positive or negative), it was necessary to evaluate a
threshold and compare the output value to that threshold, deﬁning it
as positive if the value exceeds the threshold, and negative if it does
not. Therefore, it became necessary to study cut-off points which
would best optimize the trade-off between sensitivity andbocytopenia [13]. Applying the scoring system to suspected patients produces a totaled
, moderate, and high pretest probability for heparin-induced thrombocytopenia.
Table 1
Studies included according to source, study type and laboratory test performed to
diagnose heparin-induced thrombocytopenia.





Case series SRA Positive if N50% serotonin release
in the presence of 0.1 U/mL
heparin; b20% serotonin release in
the presence of 100 U/mL heparin;
inhibition of serotonin release in
the presence of FcγII receptor-
blocking monoclonal antibody
Leong 2007 [43] Case report SRA Positive if N20% serotonin release
in the presence of 0.1 U/mLa
Girolami 2003
[25]
Cohort ELISA+HIPA It was used an antigen assay that
detects IgG antibodies against
platelet factor 4 bound to
polyvinylsulfonate (Genetic
Testing Institute, Brookﬁeld, WI).
Results were positive if N0.4 OD;
Visual evaluation of HIPA
considered a change in appearance






Cohort ELISA+HIPA The search for HIT antibodies of the
IgG class was made by a single anti-
IgG alkaline phosphatase conjugate
Fc speciﬁc (SigmaChemical, St Louis,
MO). The cut-off value of OD for the
antibody determination was 0.4 for
the antibodies mixture and 0.3 for
IgG antibodies; visual evaluation of
HIPA considered a change in






Case report SRA Not speciﬁed
Oliveira 2008
[45]
Cohort ELISAb Cases were negative in two types of
immunoassay: ID-PaGIA (Diamed)
and Asserachron HPIA (Diagnóstica
Stago). The assays were performed
according to manufacturer's
instructions
SRA: 14C-serotonin released assay; ELISA: enzyme-linked immunoassay; HIPA: heparin
induced platelet activation assay; OD: optical density.
a Besides the adoption of different criteria in comparison with the study performed
byWarkentin 1995, the interpretation of the result (7.0% of serotonin release) would be
the same independent of the interpretation criteria.
b Exclusively negative cases were extracted from this source.
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(Stata Corp, College Station, TX). Patient demographic and clinical
characteristics of HIT and no-HIT cases were compared by 2 sample t
tests for medians or proportions. The determination of accuracy was
reached by measuring the sensitivity and speciﬁcity. The ROC curve
area was used as a summary measure of test accuracy and calculated
using a nonparametric method (with asymptotic assumptions) [18].
All tests were 2-sided and considered to be statistically signiﬁcant
at pb0.05.
3. Results
A number of 186 cases were extracted from different types of
primary studies (Table 1). These cases represent the data sample of
the present report. From the total number of cases, 21 (11.3%) were
positive HIT cases and 165 (88.7%) were negative cases. Demographic
and clinical characteristics of the cases are presented in Table 2. One of
the most important characteristics of HIT, the relative drop in platelet
count, presented a signiﬁcant difference between positive HIT and
negative HIT cases (p=0.000). The positive cases showed a drop in
platelet of higher than the negative cases, varying between 49.1% and
72.3%. Among the positive HIT cases, the onset of HIT was between
days 2 and 14 (mean=7.7) which is correlated clearly with the
temporal pattern of HIT [13].
The thrombocytopenia in HIT is expected to be less severe than that
found in other forms of drug-induced thrombocytopenia [20]. Amongall
set of cases, the nadir platelet count at the time of HIT suspicionwas not
extremely low (combined mean equal to 119.1×109/L), which proved
to be similar in both groups. No statistically signiﬁcant difference in the
types of heparin used by both patient groups could be observed.
Most cases (96.2%) presented no other cause that could explain the
presence of thrombocytopenia. In only one case (0.5%) was the doctor
responsible for the case conﬁdent about the existence of another
explanation for the presence of thrombocytopenia. In 3.3% of the cases,
the existence of another cause to explain the thrombocytopeniawas not
investigated, and then it was considered possible. Among the positive
cases forHIT, 47.6%presented a thromboembolic event, 28.6%presented
skin lesions of any degree, and 4.8% (1 case) presented a disseminated
intravascular coagulation. Among the negative cases, 11.5% presented
thromboembolic events.
The 4Ts scoring system classiﬁed 57.1% of the HIT cases as having a
high score and 25.5% of the no-HIT cases as having a low score. Notably,
half of all patients (53.2%)were classiﬁed ashaving an intermediate score.
These results are shown in Table 3. The results of the ROC analysis are
shown in Table 4. A threshold set at scores 5 or 6 would represent the
optimal choice for the binary diagnosis, providing the best balance
between sensitivity and speciﬁcity. A cut-off at score 5 would, however,
maximize sensitivity, whereas a cut-off at score 6 would maximize
speciﬁcity.Moreover, upon deﬁning a cut-off point equal to 5, the 4Ts test
subsequently produces a low likelihood of false positive results and
correctly classiﬁes 55.38% of the patients. Conversely, when one deﬁnes a
cut-off point equal to 6, the same test produces a high likelihood of false
positive results and correctly classiﬁes 77.42%. The trade-off between the
clinical importance of the prompt and accurate diagnosis ofHIT, aswell as
and the risk associated with alternative anticoagulants used to treat HIT,
determines which cut point would be of interest. The estimated ROC
curve area for the 4Ts scoring system calculated a summary of the test
accuracy of equal to 0.79 (IC95% 0.69, 0.89).
4. Discussion
Clinical scoring systems are intended to quantify the combination
of several risk factors, in turn using the resulting score to estimate the
probability of a speciﬁc outcome or disease [21]. They are important in
aiding health care professionals evaluate and recognise complex and
uncommon problems. They are also of particular value in adverse drugreaction scenarios, considering that, under these circumstances,
imputability can be a challenging issue [22]. Also, thesemay represent
a simple and efﬁcient manner through which to improve clinical care.
Individual patient data represents an important sourceof knowledge
concerning a given disease. The use of these data for re-analysis of the
raw database and, if appropriate, for a combined meta-analysis, has
been explored in previous studies [23]. Thus, an individual patient data
analysis is a useful study design when a particular type of analysis is
required. This methodological approach is not feasible when data have
been destroyed or lost, or, despite every effort, when researchers do not
wish to collaborate [23]. The present analysis was possible because
individual patient data needed for the application of the 4Ts scoring
systemwere available in the studies accessed. Also, itwasnotwithin the
scope of the present study to perform ameta-analysis exploring the risk
of HIT, but rather to analyze the results of the 4Ts scoring system when
applied to the cases. Therefore, data from different study types could be
exploredwithnoundue concern regardingbias associatedwith the study
design to estimate the risk effect.Moreover, the analysis performed in the
Table 2
Demographic and clinical characteristics of the nonconcurrent cohort of cases classiﬁed
according important features for heparin-induced thrombocytopenia.
Characteristic % (n) Mean
estimation
SD 95% CI p-value
Age (year) – 67.5 13.9 65.5–69.5 –
Sex
Female 44.6 (83) – – –





Unknown 23.7 (44) 0.000
Heparin type
LMWH 45.7 (85) – – –
HIT 57.1 (12) – – –
No-HIT 44.4 (73) – – – NS
UFH 54.3 (101) – – – NS
HIT 42.9 (9) – – –
No-HIT 55.8 (92) – – –
Platelet count before
heparin exposure
HIT – 259.4 74.1 225.7–293.2
No-HIT – 213.9 70.2 203.1–224.7 0.006
Platelet count when HIT
was suspected (109/L)
–
HIT – 109.2 92.6 67.1–151.4
No-HIT – 120.4 49.8 112.7–128.0 NS
Drop in platelet count (%)
HIT – 60.7 25.5 49.1–72.3
No-HIT – 41.8 21.0 38.6–45.1 0.000
Day when HIT was suspect
HITa – 7.7 3.2 6.2–9.1
No-HIT – 8.5 7.3 7.4–9.6 NS
SD: standard deviation; 95%CI: 95% conﬁdence interval.
HIT: heparin-induced thrombocytopenia; UFH: unfractionated heparin; LMWH: low
molecular weight heparin; NS: not speciﬁed.
a Minimum: 2 days; maximum: 14 days.
Table 3
Results showing the performance of the 4Ts score system classifying the risk score for
heparin-induced thrombocytopenia of the patients studied.
Reference result Low Moderate High Total
Positive HIT 0 9 (42.9%) 12 (57.1%) 21 (100.0%)
Negative HIT 42 (25.5%) 90 (54.5%) 33 (20.0%) 165 (100.0%)
Total 42 (22.6%) 99 (53.2%) 45 (24.2%) 186 (100.0%)
Table 4
Results of the receiver operator characteristic curve (ROC curve) analysis showing
sensitivity and speciﬁcity according to scores threshold.









a All measured values above that row in the table (which are less than the threshold)
are considered negative test results, and all measured values below that row in the table
(which are greater than or equal to the threshold) are considered positive results.
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and introduced a novel approach to adverse drug reaction research.
The mean age of cases included and the proportion of males and
femaleswere similar to theﬁndingsof other studies [11,24-27]. Themean
platelet count when HIT was suspected, the average relative drop inplatelet count, and the mean day when the reaction occurred were
clinical characteristics of the set of cases that proved to be similar to HIT
patterns described in previous reports [24,25,27-29]. Also, the incidence
of clinical complications secondary to HIT was in accordance with
expected features [30-32]. The overall agreement between this non-
concurrent cohort database and the generally predicted medical in-
dications of HIT points to its consistency, reliability, and internal validity.
Sensitive assays forHIT are available, but limitations remain [8,11,33].
Functional assays are technically demanding and time-consuming, and
are mostly used for research proposes [11,34]. Commercial immunolog-
ical assays, known to identify nonplatelet-activating antibodies, may not
be routinely available to many institutions [9]. Diagnosing HIT with this
later type of laboratory test can be highly convincingwhen one considers
the strength of the reaction or when one combines it with a functional
assay to conﬁrm positive cases [7,35]. Using both an ELISA and a
functional assaywill allow for thedetectionof antibodiesdirected toward
antigens present in HIT syndrome and can be a more realistic diagnostic
tool for many institutions than performing an SRA test [33]. Indeed, the
laboratory diagnosis for HIT, as with any diagnostic instrument, presents
known limitations. However, the reference laboratory tests for HIT
considered in the present study are the most commonly considered
procedures for the deﬁnitive diagnosis of HIT [6,9,14,33].
The 4Ts scoring system was proposed to be widely used in clinical
practices. Studies performed to investigate the clinical usefulness of
this clinical scoring system have shown that a low score would rule
out HIT [14]; however, the implications of an intermediate or high
score are puzzling. Nevertheless, a diagnostic tool, such as the 4Ts
scoring system, must demonstrate the ability to differentiate not only
among the most obvious cases, but also among challenging cases. In
addition, a clinical evaluation of the risk probability for HIT produces a
critical effect on the cost-effective management of the syndrome [36],
which justiﬁes further analysis for the improvement of a scoring
system for HIT diagnosis.
In the present study, the intermediate score was attributed to 53.2%
of the cases. The uncertainty remained in intermediate scores of the
algorithm represents an important failure, in turn weakening the
diagnostic value of this screening instrument. A similar proportion of
patients who presented intermediate scores was reported in a study
regarding the usefulness of the 4Ts scoring systemwhen combinedwith
an immunoassay to diagnose heparin-induced thrombocytopenia [37].
A comparative evaluation of the 4Ts scoring system, in an attempt to log
diagnoses concerning the use of SRA and a commercial ELISA (GTI-PF4®
ELISA – GeneticTesting Institute (GTI), Waukesha, WI, USA), demon-
strated that an intermediate score was attributed to 28.6% of the cases
studied (n=100) [14]. However, the 4Ts scoring system used in this
study was modiﬁed, and comparableness of the results may be
inappropriate.
The ROC results showed two interesting score thresholds which
could be chosen to optimize both sensitivity and speciﬁcity. However,
neither cut-off points would provide a satisfactory balance between
sensitivity and speciﬁcity. This analysis shows that the pre-test
instrument would fail to distinguish between diseased and non-
diseased patients in a relevant number of cases. This result conﬁrms
the previous observation of the high level of patients classiﬁed as
within an intermediate score of risk for HIT. In fact, the intermediate
risk probability represents the challenging cases in which the clinical
scoring system is unable to differentiate properly.
The full area under the ROC curve can be interpreted as a single
index to summarize the accuracy of the test. A perfect test has an
accuracy of 1.0, whereas random chance presents an accuracy of 0.5
[18]. The 4Ts scoring system achieved an accuracy of 0.79, clearly
indicating the need for improvement.
This study is partially limited by the sources of the cases,whichwere
obtained from different study designs. However, in studies focusing on
the evaluation of adverse effects, the inclusion of several study designs,
such as cohorts, case-controls, cross sectionals, and even case series, are
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many times omit information regarding harmful effects [38]. Rather
than a lack of internal validity, the inclusion of different sources of
patients, as well as patients from different medical care settings,
improves the external validity, an important issue concerning a clinical
predictive model.
Selection bias was avoided through the development of a
comprehensive search strategy in different databases. Moreover, a
predeﬁned inclusion criterion was followed so as to avoid selection
bias based on the particular characteristics stemming from the
assessment of a wide range of studies. Bias introduced by differences
in patients' treatments is unlikely, as no correlation between the
development of HIT and the administration route (IV versus SC) is
referred in the literature, and considering that even low amounts of
heparin can induce HIT [39,40].
Evaluating the accuracy of diagnostic instruments is an important
issue, since it can leads to the improvement of health care
interventions. A number of studies have been investigating the
usefulness of combining the 4Ts scoring system and laboratory testing
in the diagnosis of HIT [37,41]. However, a standardised approach in
which the association of a clinical prediction model and a single
immunoassay could diagnose HIT warrants further investigation.
Ideally, a scoring system able to diagnose HIT without the need for
laboratory assays would greatly reduce ﬁnancial and time constraints.
In this light, the 4Ts scoring system, as compared to reference
laboratory diagnoses, represents an important diagnostic tool in HIT
scenarios which demand improvements in terms of accuracy. Further
studies regarding clinical prediction models for the diagnosis of HIT
are necessary to improve the early recognition of this adverse drug
reaction and to provide better medical care for at-risk patients.
5. Conclusion
Our results suggest that the 4Ts scoring system was unable to
satisfactorily identify the probability of HIT in approximately half of
the cases with a clinical suspicion of this adverse drug reaction.
Different cut-off points for the continuous scale of this scoring system
demonstrated no improvement in the screening ability of this
diagnostic tool. The analysis performed may well represent an
interesting approach to the use of individual patient data in adverse
drug reaction studies.
Acknowledgements
This study was supported by the Coordination for the Improve-
ment of Higher Level Education (CAPES), the National Council of
Technological and Scientiﬁc Development, CNPq, (Process Number
554725/2009-6) in the form of a post-graduate scholarship, and by
the Research Foundation of the State of Minas Gerais, Fapemig,
(Process number APQ-01149-08), Brazil.
References
[1] Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the
Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest
2004;126:338S–400S.
[2] Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the
target for antibodies generated in heparin-induced thrombocytopenia. Thromb
Haemost 1992;68:95–6.
[3] Chong BH, Murray B, Berndt MC, Dunlop LC, Brighton T, Chesterman CN. Plasma
P-selectin is increased in thrombotic consumptive platelet disorders. Blood
1994;83:1535–41.
[4] Keeling D, Davidson S, Watson H. The management of heparin-induced
thrombocytopenia. Br J Haematol 2006;133:259–69.
[5] Warkentin TE, Greinacher A, Koster A, Lincoff M. Treatment and prevention of
heparin-induced thrombocytopenia. Chest 2008;133:340–80.
[6] Otis SA, Zehnder JL. Heparin-induced thrombocytopenia: current status and
diagnostic challenges. Am J Hematol 2010;85:700–6.[7] Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombo-
cytopenia. Blood 1986;67:27–30.
[8] Pouplard C, Amiral J, Borg JY, Laporte-Simitsidis S, Delahousse B, Gruel Y. Decision
analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and
heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of
heparin-induced thrombocytopenia. Am J Clin Pathol 1999;111:700–6.
[9] Greinacher A. Heparin-induced thrombocytopenia. J Thromb Haemost 2009;7:
9–12.
[10] Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition,
treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and
Thrombolytic Therapy. Chest 2004;126:311S–37S.
[11] Crowther MA, Cook DJ, Albert M et al. The 4Ts scoring system for heparin-induced
thrombocytopenia in medical-surgical intensive care unit patients. J Crit Care
2010.
[12] Kottke-Marchant K, Bontempo FA. A positive in vitro assay is required to diagnose
heparin-induced thrombocytopenia. Med Clin North Am 2003;87:1215–24.
[13] Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and manage-
ment. Br J Haematol 2003;121:535–55.
[14] Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of
pretest clinical score (4T's) for the diagnosis of heparin-induced thrombocytope-
nia in two clinical settings. J Thromb Haemost 2006;4:759–65.
[15] Lilienfeld DE, Stolley PD. Foundations of epidemiology. 3 ed. New York: Oxford
University; 1994.
[16] Commitee for medicinal products for human use (CHMP). Guideline on clinical
investigation of medical products for prophylaxis of high intra- and post-
operative venous thromboembolic risk. EuropeanMedicines Agency (Emea) 2007.
[17] Creager MA, Dzau VJ. Vascular disease of extremities. In: Kasper DL, Braunwald E,
Fauci AS, Hauser SL, Long DL, Jameson JL, editors. Harrison's Principles of Internal
Medicine. 16 ed. New York: McGraw-Hill; 2006. p. 1486–94.
[18] Lasko TA, Bhagwat JG, Zou KH, Ohno-Machado L. The use of receiver operating
characteristic curves in biomedical informatics. J Biomed Inform 2005;38:404–15.
[19] Obuchowski NA. Receiver operating characteristic curves and their use in
radiology. Radiology 2003;229:3–8.
[20] Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med
2007;357:580–7.
[21] Gunning K, Rowan K. ABC of intensive care: outcome data and scoring system. BMJ
1999;319:241–4.
[22] Strom BL. Pharmacoepidemiology3. . New York: Wiley; 2000.
[23] Stewart LA, Tierney JF, Clarke M. Reviews of individual patient data. In: Higgins
JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions,
Version 5.0.1 ed. The Cochrane Collaboration, 2008.
[24] Prandoni P, Siragusa S, Girolami B, Fabris F. The incidence of heparin-induced
thrombocytopenia in medical patients treated with low-molecular-weight
heparin: a prospective cohort study. Blood 2005;106:3049–54.
[25] Girolami B, Prandoni P, Stefani PM, Tanduo C, et al. The incidence of heparin-
induced thrombocytopenia in hospitalized medical patients treated with
subcutaneous unfractionated heparin: a prospective cohort study. Blood
2003;101:2955–9.
[26] Sturtevan JM, Pillans PI, Mackenzie F, Gibbs HH. Heparin-induced thrombocyto-
penia: recent experience in a large teaching hospital. Intern Med J 2006;36:431–6.
[27] Lubenow N, Kempf R, Eichner A, Eichler P, et al. Temporal pattern of
thrombocytopenia in relation to initial use or reexposure to heparin. Chest
2002;122:37–42.
[28] Aster RH, Bougie DW. Drug-induced thrombocytopenia. N Engl J Med 2007;357:
580–7.
[29] Arepally GM. Heparin-induced thrombocytopenia. N Engl J Med 2006;355:
809–17.
[30] Warkentin TE. Think of HIT. Hematology 2006;408–14.
[31] Warkentin TE. Heparin-induced thrombocytopenia. Hematol Oncol Clin North Am
2007;21:589–607 v.
[32] Warkentin TE, Roberts RS, Hirsh J, Kelton JG. Heparin-induced skin lesions and
other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a
nested cohort study. Chest 2005;127:1857–61.
[33] Eichler P, Budde U, Haas S, et al. First workshop for detection of heparin-induced
antibodies: validation of the heparin-induced platelet-activation test (HIPA) in
comparison with a PF4/heparin ELISA. Thromb Haemost 1999;81:625–9.
[34] Bidet A, Tardy Poncet B, Desprez D et al. Clinical characteristics and laboratory
testing of patients with suspected HIT: A survey on current practice in 11
university hospitals in France. Thromb Res 2010.
[35] Leo A, Winteroll S. Laboratory diagnosis of heparin-induced thrombocytopenia
and monitoring of alternative anticoagulant. Clin Diagn Lab Immunol 2003;10:
731–40.
[36] Patrick AR, Winkelmayer WC, Avorn J, Fischer MA. Strategies for the management
of suspected heparin-induced thrombocytopenia: a cost-effectiveness analysis.
Pharmacoeconomics 2007;25:949–61.
[37] Gruel Y, Regina S, Pouplard C. Usefulness of pretest clinical score (4Ts) combined
with immunoassay for the diagnosis of heparin-induced thrombocytopenia. Curr
Opin Pulm Med 2008;14:397–402.
[38] Loke YK, Price D, Herxheimer A. Systematic reviews of adverse effects: framework
for a structured approach. BMC Med Res Methodol 2007;7:32.
[39] Gettings EM, Brush KA, Cott EMV, HurfordWE. Outcome of postoperative critically
ill patients with heparin-induced thrombocytopenia: an observational retrospec-
tive case-control study. Crit Care 2006;10:161–7.
[40] Vezali E, Elefsiniotis I, Pironaki M, Boltsis N, Paizis V, Moulakakis. Heparin-induced
thrombocytopenia due to heparin ﬂushes: report of two cases. Int J Clin Pract
2007;61:514–8.
1526 D.R.G. Junqueira et al. / Clinica Chimica Acta 412 (2011) 1521–1526[41] Denys B, Stove V, Philippe J, Devreese K. A clinical-laboratory approach
contributing to a rapid and reliable diagnosis of heparin-induced thrombocyto-
penia. Thromb Res 2008;123:137–45.
[42] Warkentin TE. Heparin-induced skin lesions. Br J Haematol 1996;92:494–7.
[43] Leong WA. Case studies in anticoagulant management. J Thromb Thrombolysis
2008;25:78–84.[44] Plassat R, Cognet F, Ternisien C, et al. Heparin-induced thrombocytopenia: case
report and literature review [in French]. Ann Readapt Med Phys 2002;45:
216–23.
[45] Oliveira SC, Bydlowski SP. Heparin-induced thrombocytopenia: clinical and
laboratorial aspects [in Portuguese]. Brazil: University of São Paulo; 2008. 18-5-2010.
